1.
Zhivaki D, Kennedy SN, Park J, et al. Correction of age-associated defects in dendritic cells enables CD4 T cells to eradicate tumors. Cell. 2024. doi:10.1016/j.cell.2024.05.026.
1.
Zarif TE, Semaan K, Eid M, et al. Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma. Cell reports. 2024;43(6):114350. doi:10.1016/j.celrep.2024.114350.
1.
Wohlfarth J, Kosnopfel C, Faber D, et al. Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular oncology. 2024. doi:10.1002/1878-0261.13660.
1.
Wohlfarth J, Kosnopfel C, Faber D, et al. Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density. Molecular oncology. 2024. doi:10.1002/1878-0261.13660.
1.
Miranda A, Shirley CA, Jenkins RW. Emerging roles of TBK1 in cancer immunobiology. Trends in cancer. 2024. doi:10.1016/j.trecan.2024.02.007.
1.
Ruiz-Torres DA, Naegele S, Podury A, Wirth L, Shalhout SZ, Faden DL. Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis. Oral oncology. 2024;151:106761. doi:10.1016/j.oraloncology.2024.106761.
1.
Revach O-Y, Cicerchia AM, Shorer O, et al. Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.02.12.579184.
1.
Petralia F, Ma W, Yaron TM, et al. Pan-cancer proteogenomics characterization of tumor immunity. Cell. 2024. doi:10.1016/j.cell.2024.01.027.
1.
Patel AG, Ashenberg O, Collins NB, et al. A spatial cell atlas of neuroblastoma reveals developmental, epigenetic and spatial axis of tumor heterogeneity. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.01.07.574538.
1.
Wang M, Ran X, Leung W, et al. ATR inhibition induces synthetic lethality in mismatch repair-deficient cells and augments immunotherapy. Genes & development. 2023;37(19-20):929-943. doi:10.1101/gad.351084.123.